Canaccord Genuity discretionary clients have further reduced their stake in oil and gas company Westmount Energy (LON: WTE) from 6.87% to 0.001%. Management says there are no material changes in trading. The share price soared 129% to 1.95p.
At the end of week, there was significant trading in the shares of Trellus (LON: TRLS), which has developed a digital platform to manage complex chronic conditions. This is already the most shares traded in a single day since February. The share price jumped to 1.65p and ended the week up 69.2% to 1.1p.
SIMEC Atlantis Energy (LON: SAE) has reached financial close on the AW1 BESS project in South Wales. This is a 120MW generation project and construction has begun at Uskmouth. A global renewable energy partner is taking a 24.7% stake in the project. Zeus has increased the 2025 revenues forecast from £7.4m to £11.4m and the 2026 estimate from £7.5m to £12.5m. In each year the expected loss has been more than halved to around £3m. Net debt is expected to be £65.1m at the end of 2025 and rise to £99.9m one year later. The share price increased 63.2% to 3.1p.
Northern Standard has reduced its shareholding in Aptamer (LON: APTA) from 10.9% to 8.14%. Oberon Investments has raised its stake from 6.08% to 6.47%. This includes previous holdings of Crux and Lansdowne. The share price rose 56.9% to 0.565p.
FALLERS
Defence contractor RC Fornax (LON: RCFX) was heavily traded on Friday. There have not been as many trades in a single day since early April, not even when the profit warning was announced. The share price slumped 29.3% to 14.5p.
Restaurants operator Tasty (LON: TAST) raised £9.25m from a placing at 0.5p/share and a retail offer generated a further £870,00o. The Kaye family invested £500,000 in the retail offer. There will be £3m invested in the existing restaurants and a further £1m on operational efficiency. There will be £3.6m set aside to acquire restaurant brands. The share price lost some of last week’s gains and was down 27.3% to 0.6p.
Alex Duggan has been appointed interim chief executive of erectile dysfunction treatments developer Futura Medical (LON: FUM). Angela Hildreth is stepping down as finance director and has a six-month notice period. Eroxon sales remain unpredictable. Sales and marketing strategies are being assessed and there will be news when the interims are published in late September. The share price fell 25.2% to 9.35p.
Drug developer ImmuPharma (LON: IMM) reported a reduction in loss from £2.78m to £1.95m in the six months to June 2025. The underlying improvement is masked by a loss on a derivative asset. Studies have helped to strengthen the commercial viability of the P140 technology platform and discussions continue with potential partners. The share price declined 24% to 1.58p.
Anexo (LON: ANX) says its tender offer was heavily oversubscribed with 32.17 million shares tendered with excess tenders scaled back so that 20 million shares were purchased. At 60p/share, there was £20m returned to shareholders. There are 97.99 million shares in issue following the tender. Independent directors have recommended a 60p/share bid. The share price slipped 19.8% to 38.5p.